File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma

TitleAdverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma
Authors
KeywordsHepatocellular carcinoma
Immune infiltration
Pan-cancer
Rho GTPases
Single-cell transcriptome
Issue Date31-Jan-2024
PublisherBioMed Central
Citation
Journal of Translational Medicine, 2024, v. 22, n. 1 How to Cite?
Abstract

Background: Emerging evidence suggests that Rho GTPases play a crucial role in tumorigenesis and metastasis, but their involvement in the tumor microenvironment (TME) and prognosis of hepatocellular carcinoma (HCC) is not well understood. Methods: We aim to develop a tumor prognosis prediction system called the Rho GTPases-related gene score (RGPRG score) using Rho GTPase signaling genes and further bioinformatic analyses. Results: Our work found that HCC patients with a high RGPRG score had significantly worse survival and increased immunosuppressive cell fractions compared to those with a low RGPRG score. Single-cell cohort analysis revealed an immune-active TME in patients with a low RGPRG score, with strengthened communication from T/NK cells to other cells through MIF signaling networks. Targeting these alterations in TME, the patients with high RGPRG score have worse immunotherapeutic outcomes and decreased survival time in the immunotherapy cohort. Moreover, the RGPRG score was found to be correlated with survival in 27 other cancers. In vitro experiments confirmed that knockdown of the key Rho GTPase-signaling biomarker SFN significantly inhibited HCC cell proliferation, invasion, and migration. Conclusions: This study provides new insight into the TME features and clinical use of Rho GTPase gene pattern at the bulk-seq and single-cell level, which may contribute to guiding personalized treatment and improving clinical outcome in HCC.


Persistent Identifierhttp://hdl.handle.net/10722/354430

 

DC FieldValueLanguage
dc.contributor.authorYang, Qi-
dc.contributor.authorZhuo, Zewei-
dc.contributor.authorQiu, Xinqi-
dc.contributor.authorLuo, Ruibang-
dc.contributor.authorGuo, Kehang-
dc.contributor.authorWu, Huihuan-
dc.contributor.authorJiang, Rui-
dc.contributor.authorLi, Jingwei-
dc.contributor.authorLian, Qizhou-
dc.contributor.authorChen, Pengfei-
dc.contributor.authorSha, Weihong-
dc.contributor.authorChen, Hao-
dc.date.accessioned2025-02-08T00:51:18Z-
dc.date.available2025-02-08T00:51:18Z-
dc.date.issued2024-01-31-
dc.identifier.citationJournal of Translational Medicine, 2024, v. 22, n. 1-
dc.identifier.urihttp://hdl.handle.net/10722/354430-
dc.description.abstract<p>Background: Emerging evidence suggests that Rho GTPases play a crucial role in tumorigenesis and metastasis, but their involvement in the tumor microenvironment (TME) and prognosis of hepatocellular carcinoma (HCC) is not well understood. Methods: We aim to develop a tumor prognosis prediction system called the Rho GTPases-related gene score (RGPRG score) using Rho GTPase signaling genes and further bioinformatic analyses. Results: Our work found that HCC patients with a high RGPRG score had significantly worse survival and increased immunosuppressive cell fractions compared to those with a low RGPRG score. Single-cell cohort analysis revealed an immune-active TME in patients with a low RGPRG score, with strengthened communication from T/NK cells to other cells through MIF signaling networks. Targeting these alterations in TME, the patients with high RGPRG score have worse immunotherapeutic outcomes and decreased survival time in the immunotherapy cohort. Moreover, the RGPRG score was found to be correlated with survival in 27 other cancers. In vitro experiments confirmed that knockdown of the key Rho GTPase-signaling biomarker SFN significantly inhibited HCC cell proliferation, invasion, and migration. Conclusions: This study provides new insight into the TME features and clinical use of Rho GTPase gene pattern at the bulk-seq and single-cell level, which may contribute to guiding personalized treatment and improving clinical outcome in HCC.</p>-
dc.languageeng-
dc.publisherBioMed Central-
dc.relation.ispartofJournal of Translational Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectHepatocellular carcinoma-
dc.subjectImmune infiltration-
dc.subjectPan-cancer-
dc.subjectRho GTPases-
dc.subjectSingle-cell transcriptome-
dc.titleAdverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma-
dc.typeArticle-
dc.identifier.doi10.1186/s12967-024-04926-0-
dc.identifier.pmid38297333-
dc.identifier.scopuseid_2-s2.0-85183705052-
dc.identifier.volume22-
dc.identifier.issue1-
dc.identifier.eissn1479-5876-
dc.identifier.issnl1479-5876-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats